에티오피아 제약 등급 락토스 공급업체 및 가격 — 마켓 오버뷰 2026

상위 제품

유당

최종 업데이트

2026-08-23

서치 및 소싱 팀을 위한 핵심 요약

페이지 데이터 최종 업데이트일: 2026-08-23.

소싱 진단

에티오피아산 제약 등급 락토스, 우리도 들여올 수 있을까요?

필요한 스펙과 물량만 알려주세요. 실제로 소싱이 되는지, 어떤 원산지와 공급사가 맞는지 무료로 짚어드려요.

에티오피아의 제약 등급 락토스 수입 바이어 인텔리전스 및 가격 시그널: 바이어, 수요, 거래 파트너

에티오피아의 제약 등급 락토스에 대해 수입 파트너 기업 1개가 추적됩니다. 수출업체와 수입업체는 Supply Chain Intelligence 회사 프로필 및 분석을 활용해 바이어 수요, 파트너 밀도, 다운스트림 채널을 분석할 수 있습니다.

스캐터 포인트는 전체 거래 데이터셋의 100.0%에서 샘플링되었습니다.

제약 등급 락토스의 에티오피아 샘플 수입 거래 및 가격 기록

에티오피아의 제약 등급 락토스 샘플 수입 거래 5건은 가격 수준과 수요 측 거래 패턴 벤치마킹을 위한 날짜, 원산지, 무역 국가 맥락을 제공합니다.

에티오피아의 제약 등급 락토스 샘플 수입 거래 단가(일자별): 2026-06-14: 3.07 USD / kg, 2026-03-29: 3.07 USD / kg, 2026-02-14: 3.07 USD / kg, 2026-01-17: 3.45 USD / kg, 2026-01-16: 3.43 USD / kg.

일자	신고 품목	단가	수출업체	수입업체	원산지
2026-06-14	THI *** ************ *** * ** ********** * ******************	3.07 USD / kg	(-)	(-)	-
2026-03-29	THI *** ************ *** * ** ********** * ******************	3.07 USD / kg	(-)	(-)	-
2026-02-14	THI *** ************ *** * ** ********** * ******************	3.07 USD / kg	(-)	(-)	-
2026-01-17	PHA********* * ****** *** ******* * * ******	3.45 USD / kg	(-)	(-)	-
2026-01-16	PHA********* * ****** *** ******* * * ******	3.43 USD / kg	(-)	(-)	-

에티오피아 내 상위 제약 등급 락토스 바이어, 수입업체 및 수요 파트너

선도 바이어 프로필을 검토하고 에티오피아의 제약 등급 락토스에 대해 추적되는 전체 수입 파트너 기업 1개와 비교하세요. 수출업체와 수입업체는 Supply Chain Intelligence 회사 프로필 및 분석으로 수요 측 파트너 적합도를 평가할 수 있습니다.

(에티오피아)

최근 수입 거래: 2026-07-23

산업군: 작물 생산식품 제조식품 포장기타

밸류체인 역할: 유통 / 도매농업 / 생산 / 가공 / 포장식품 제조기타

에티오피아 수입 파트너 커버리지

1개 기업

수입 파트너 기업 수는 에티오피아의 제약 등급 락토스 수요 측 가시성을 보여줍니다.

공급망 인텔리전스 분석과 기업 프로필을 활용해 에티오피아에서 활동 중인 제약 등급 락토스 수입업체, 유통업체, 바이어 네트워크를 식별하세요.

수출 진단

우리 제약 등급 락토스, 이 에티오피아 바이어들에게 팔 수 있을까요?

만드시는 제품만 알려주시면 됩니다. 지금 수출할 준비가 됐는지, 어느 시장이 맞는지 무료로 봐드려요.

가격 데이터

가려진 에티오피아 제약 등급 락토스 가격, 열어볼까요?

전체 가격 히스토리와 경쟁사 벤치마크를 열어드립니다. 어떤 숫자가 필요하신지만 말씀해 주시면 함께 살펴봐 드려요.

Classification

Product TypeIngredient

Product FormPowder

Industry PositionPharmaceutical excipient (dairy-derived carbohydrate used in drug formulation)

Market

Pharmaceutical-grade lactose in Ethiopia functions primarily as an imported excipient used by domestic finished-dosage manufacturers (notably tablet and capsule production) and by regulated importers/distributors supplying manufacturers and healthcare markets. Ethiopia’s pharmaceutical market is structurally import-dependent, and local manufacturers commonly rely on imported raw materials, including excipients, which increases exposure to foreign-exchange availability and import-permit lead times. EFDA’s regulatory controls for medicines and medicine raw materials (including port-clearance procedures and risk-based inspection) shape market access and shipment release timelines. Public sources do not indicate established domestic production of pharmaceutical-grade lactose in Ethiopia, so supply continuity is mainly driven by importer qualification, supplier GMP/GDP assurance, and logistics via the Djibouti corridor.

Market RoleImport-dependent pharmaceutical excipient market (net importer)

Domestic RoleExcipient input for local formulation and packaging of finished pharmaceuticals; predominantly supplied via imports and domestic distribution.

Market GrowthGrowing (Recent multi-year trend cited by investment and sector sources)Demand growth driven by expanding pharmaceutical consumption and import-substitution policy emphasis, with raw-material procurement constrained by FX availability.

Specification

Physical Attributes

Free-flowing crystalline powder grade suitable for blending and compression (flowability and particle-size control are key to tablet/capsule uniformity).
Moisture sensitivity (caking/clumping risk) requires dry storage and humidity control during inland transport and warehousing.

Compositional Metrics

Compendial conformity is typically demonstrated via pharmacopeial monograph testing (identity/assay, water content, microbial limits, and impurity controls) aligned to USP/Ph. Eur. expectations claimed by the supplier.

Grades

USP/NF compliant lactose (where claimed by supplier)
Ph. Eur. compliant lactose (where claimed by supplier)
Buyer-approved house specification aligned to a recognized pharmacopeia when compendial grade is required

Packaging

Sealed moisture-barrier inner liner with labeled outer packaging showing manufacturer, batch/lot, net weight, and storage conditions.
Batch Certificate of Analysis (CoA) and distribution traceability documentation aligned to excipient GDP expectations.

Supply Chain

Value Chain

Qualified excipient manufacturer → exporter/distributor → international freight to Djibouti → inland transport to Ethiopia → GDP/GMP-aligned warehousing → importer/manufacturer incoming QC (identity verification/CoA review) → released for use in finished-dosage manufacture

Temperature

Ambient shipment and storage are typical, but protection from heat/humidity is important to prevent moisture uptake and caking during long inland dwell times.

Atmosphere Control

Keep containers sealed; minimize exposure to humid air during transloading and warehouse handling.

Shelf Life

Landed usability is sensitive to moisture exposure and packaging integrity; extended port/corridor delays increase the risk of caking and out-of-spec moisture.

Freight IntensityLow

Transport ModeMultimodal

Risks

Foreign Exchange HighForeign-exchange availability and import financing (e.g., LC access) can delay or block procurement of imported pharmaceutical raw materials, including excipients like pharmaceutical-grade lactose, disrupting manufacturing continuity.Build safety stock based on realistic LC/FX lead times; diversify qualified suppliers and shipment schedules; align procurement with any priority-forex or duty/permit facilitation channels applicable to medicinal products and raw materials.

Regulatory Compliance HighEFDA port-clearance and risk-based inspection/sampling can delay release if documentation is incomplete or if the shipment is selected for sampling; mismatches between CoA, labels, and shipping documents increase detention risk.Pre-verify a single controlled document pack (invoice, packing list, CoA, labels, permits) and ensure batch/lot consistency across all documents before dispatch.

Quality MediumRisk of substandard, substituted, or improperly handled excipients is elevated when GDP controls are weak, particularly across multi-leg inland logistics with extended dwell times.Source from audited/qualified suppliers (e.g., EXCiPACT or equivalent), require GDP-aligned distribution controls, and perform incoming QC/identity testing at the manufacturing site before use.

Logistics MediumExtended corridor transit times and port/inland delays can increase moisture exposure risk (caking) and raise landed costs through storage/demurrage, especially for hygroscopic powders.Use moisture-protective packaging, minimize transloading exposure, specify covered/controlled storage, and track humidity/pack integrity on receipt.

Sustainability

Landlocked logistics footprint: imports typically transit via seaport-to-inland corridor, increasing handling steps and emissions per delivered ton compared with coastal markets.
Animal-origin traceability: lactose is dairy-derived; buyers may require documentation on source material controls and allergen management within the excipient supply chain.

Standards

EXCiPACT GMP/GDP certification (commonly used third-party scheme for excipient manufacturers/distributors)
IPEC-PQG GMP Guide (industry GMP expectations for excipient manufacture)
IPEC Good Distribution Practices (GDP) Guide for pharmaceutical excipients

FAQ

Is Ethiopia mainly an importer or a producer of pharmaceutical-grade lactose?Based on public sources used in this record, Ethiopia should be treated as an import-dependent market for pharmaceutical-grade lactose used as an excipient. Sector sources describe heavy import reliance for pharmaceuticals and imported raw materials, and no established domestic production of pharmaceutical-grade lactose is evidenced in the cited materials.

What is the biggest trade-disrupting risk for importing pharmaceutical excipients like lactose into Ethiopia?The most critical risk is foreign-exchange availability for imports, which can delay or block procurement and shipment clearance processes tied to import financing. IMF and Ethiopia-focused importer surveys describe FX shortages as a major constraint affecting the ability to import.

Which Ethiopian authority and process is most relevant for clearing medicine raw materials at the port of entry?EFDA is the key authority for medicines and medicine raw materials, and it publishes a port-clearance guideline that describes documentation expectations and risk-based inspection/sampling for pharmaceutical consignments and related raw materials.